
|Articles|November 28, 2011
Mark Zitter Addresses How Oncology Payers Are Becoming Stricter About Covered Therapies
Advertisement
Mark Zitter, Founder and CEO of The Zitter Group, in San Francisco and Millburn, NJ, discusses how oncology payers are tightening the reins with approval requirements and the delicacy involved in revising guidelines around cancer care.
Mr. Zitter talks about several of the payers' changes, which include prior authorizations, clinical guidelines, and decision-support programs. He also addresses the ongoing friction between payers and providers and how critical it is to find resolution.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Clears First Alzheimer Blood Test for Adults as Young as 40
2
MFN Drug Agreements Could Raise Prices Worldwide
3
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
4
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
5




